Welcome to our dedicated page for Organogenesis Hldgs news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Hldgs stock.
Organogenesis Holdings Inc. (Nasdaq: ORGO) is a regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. The Organogenesis news feed highlights company announcements, clinical updates, financial results, and regulatory developments that help investors and healthcare professionals understand how the business is evolving.
News about Organogenesis frequently covers its regenerative medicine portfolio and its position in the skin substitutes and cellular and tissue-based products (CTP) market. The company issues press releases on quarterly and year-to-date financial performance, including net product revenue from Advanced Wound Care and Surgical & Sports Medicine products, net income or loss, and adjusted metrics such as adjusted net income and adjusted EBITDA. These updates often include management commentary on market conditions, reimbursement dynamics, and expectations for future periods.
A major theme in Organogenesis news is the development of ReNu, a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis. The company publishes detailed updates on Phase 3 randomized controlled trials, including pain and function outcomes, safety observations, and plans for regulatory submissions. Announcements have described FDA Regenerative Medicine Advanced Therapy (RMAT) designation for ReNu, plans for a Biologics License Application (BLA), and the initiation of a rolling BLA submission.
Additional news items include commentary on Centers for Medicare & Medicaid Services (CMS) payment reforms for skin substitutes/CTPs, participation in investor conferences, and corporate governance developments such as inducement equity grants and stockholder meeting results. By following this page, readers can review a chronological record of how Organogenesis communicates its financial performance, clinical progress, reimbursement environment, and corporate actions.
Organogenesis Holdings Inc. (Nasdaq: ORGO) announced the appointment of Prathyusha Duraibabu to its Board of Directors as of November 19, 2021. Ms. Duraibabu brings over 24 years of expertise in technology and healthcare, having held senior roles at global biotechnology firms. Currently the CFO of Sangamo Therapeutics, she has also served as Corporate Controller at Pacific Biosciences. The addition is expected to enhance the Board's strategic insight and oversight, particularly within the Audit Committee.
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported Q3 2021 net revenue of $113.8 million, a 13% increase year-over-year. Advanced Wound Care products drove revenue growth, contributing $107.3 million, up 19% compared to Q3 2020. However, Surgical & Sports Medicine revenue fell 41% to $6.4 million. Net income decreased to $12.6 million from $20.8 million in Q3 2020. Operating expenses rose 30% to $71.3 million, impacting profitability. The company forecasts 2021 net revenue between $458 million and $470 million, a 35% to 39% increase year-over-year.
Organogenesis Holdings (Nasdaq: ORGO) will participate in the Credit Suisse 30th Annual Healthcare Conference from November 8-11, 2021. A fireside chat featuring company management is scheduled for November 11 at 9:40 a.m. ET. The event will be held virtually, and a live audio webcast will be accessible via the ‘Upcoming Events’ section on Organogenesis’s Investor Relations page. An archived version of the webcast will be available for 30 days post-conference.
Organogenesis specializes in regenerative medicine, offering bioactive products for advanced wound care and surgical markets.
Organogenesis Holdings Inc. (Nasdaq: ORGO) will showcase advanced wound care research at the 2021 Symposium on Advanced Wound Care Fall Conference in Las Vegas from October 29-31. Key presentations include a lunch symposium discussing in vivo data on PuraPly technology and a session on dermal substitutes post-Mohs surgery. The company also highlights its Adjustable Curette, aimed at enhancing wound debridement. Organogenesis, a leader in regenerative medicine, focuses on innovative solutions for advanced wound care and surgical applications.
Organogenesis Holdings Inc. (Nasdaq: ORGO) announced that it will release its third-quarter financial results on November 9, 2021, after the market closes. The company will hold a conference call at 5:00 p.m. ET the same day to discuss these results and provide updates on corporate developments. Participation can be done via a dedicated phone line and a live webcast will be available on their investor relations website. Organogenesis specializes in regenerative medicine, focusing on advanced wound care and surgical biologics.
Organogenesis Holdings has announced their participation in two significant investor conferences. The management will engage in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14th at 1:15 p.m. ET. Additionally, they will present at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on September 20th at 3:45 p.m. ET. Live audio webcasts will be available on their website, with replays accessible for 30 days post-conference.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has partnered with Net Health to become the first to utilize Net Health's CTP Connections Module, enabling the electronic submission of insurance benefits verification forms. This initiative aims to enhance efficiency for hospital and outpatient wound care providers in verifying benefits for Organogenesis's cell and tissue-based products. The service is provided at no extra cost to Net Health Wound Care users, minimizing administrative errors and speeding up responses from payors, ultimately improving patient access to critical products.
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported robust financial results for Q2 2021, with net revenue reaching $123.2 million, a 79% increase year-over-year. Key drivers included Advanced Wound Care products at $111.4 million (up 87%) and Surgical & Sports Medicine at $11.8 million (up 27%). The company achieved a net income of $20.7 million, reversing a loss of $5.2 million in Q2 2020. Adjusted EBITDA increased to $25.1 million, or 20.4% of net revenue, compared to $0.3 million in the prior year.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has announced a new credit agreement with Silicon Valley Bank, introducing a $200 million credit facility. This includes a $75 million term loan and a $125 million revolving credit line, aimed at general corporate purposes and repaying an existing $100 million facility. Senior VP Henry Hagopian emphasized that this agreement will lower borrowing costs and support long-term growth. The partnership reflects the bank's commitment to the company’s innovation in advanced healing solutions.
Organogenesis Holdings Inc. (Nasdaq: ORGO) plans to release its second-quarter fiscal year 2021 financial results on August 9, after market close. The management will host a conference call at 5:00 p.m. ET on the same day to discuss the results, followed by a Q&A session. Interested participants can join the call via phone or through a live webcast available on the company's investor relations website. A replay will be accessible for two weeks post-call. Organogenesis specializes in regenerative medicine focused on advanced wound care and surgical solutions.